Angiotensin II receptors blockers in the treatment of patients with cardiorenal syndrome

Cover Page


Cite item

Full Text

Abstract

Literature review on the use of angiotensin II receptors blockers in patients with combined pathology of the cardiovascular and renal systems: chronic heart failure and chronic kidney disease is presented. The angiotensin II receptors blockers positive effect is determined by the selective and complete type 1 receptors blockade and simultaneous stimulation of the type 2 receptors. On the one hand angiotensin II blockers are well-studied and widely used class of drugs in patients with cardiac pathology. On the other hand, the efficacy and safety of this drugs group in patients with renal impairment due to cardiac pathology or coexisting urinary system diseases are not well studied. Clinical studies have confirmed the angiotensin II receptor blockers pharmacotherapeutic activity and safety in reducing the cardiovascular events rate, including cardiovascular mortality, myocardial infarction, stroke, number of hospitalizations due to decompensated heart failure. There is data regarding the heart failure poor prognosis in decreased kidney function, but most of these studies were conducted in patients with end-stage renal failure. Data on angiotensin II receptor blockers effect on the course and prognosis of patients with heart failure in association with kidney damage is not enough. The effect of angiotensin II on the heart failure clinical presentation and outcomes according to the left ventricular ejection fraction preservation or reduction, and on the severity of kidney damage is not studied.

About the authors

A A Nasybullina

Kazan State Medical University, Kazan, Russia

Author for correspondence.
Email: almed-89@mail.ru

O V Bulashova

Kazan State Medical University, Kazan, Russia

Email: almed-89@mail.ru

E V Khazova

Kazan State Medical University, Kazan, Russia

Email: almed-89@mail.ru

V M Gazizyanova

Kazan State Medical University, Kazan, Russia

Email: almed-89@mail.ru

M I Malkova

Kazan State Medical University, Kazan, Russia

Email: almed-89@mail.ru

References

  1. Агеев Ф.Т., Беленков Ю.Н., Фомин И.В. и др. Распространённость хронической сердечной недостаточности в Европейской части Российской Федерации - данные ЭПОХА-ХСН. Ж. сердечн. недостаточность. 2006; 7 (1): 112-115.
  2. Богданова А.Р., Сигитова О.Н. Современные принципы диагностики ишемической болезни почек. Вестн. соврем. клин. мед. 2014; 7 (1): 46-52.
  3. Кобалава Ж.Д., Гудков К.М. Эволюция представлений о стресс-индуцированной артериальной гипертонии и применение антагонистов рецепторов ангиотензина II. Кардиоваск терап. и проф. 2002; (1): 4-15.
  4. Кузьмин О.Б. Механизмы развития и прогрессирования нефропатии у больных сердечной недостаточностью с хроническим кардиоренальным синдромом. Нефрология. 2011; 15 (2): 20-29.
  5. Кукес В.Г. Клиническая фармакология. М.: ГЭОТАР-Медиа. 2008; 320 с.
  6. Мареев В.Ю. Антагонисты рецепторов к ангиотензину II в клинической практике в начале XXI века. Яркий свет в конце длинного тоннеля. Consil. med. 2001; 3 (2): 73-78.
  7. Максимов М.Л., Дербенцева Е.А., Дралова О.В. и др. Применение блокатора АТ1 рецепторов ангиотензина II валсартана у пациентов с хронической сердечной недостаточностью. Ж. сердечн. недостаточность. 2010; 11 (5): 301-305.
  8. Недогода С.В. Возможности сартанов в коррекции когнитивных нарушений при артериальной гипертонии. Систем. гипертенз. 2012; 1 (9): 11-14.
  9. Cигитова О.Н., Саубанова Э.Н. Анализ влияния протеинурического и непротеинурического вариантов гипертонической нефропатии на ремоделирование миокарда. Дневник казан. мед. школы. 2014; 11 (V): 6-9.
  10. Cигитова О.Н., Архипов Е.В. Хроническая болезнь почек: новое в классификации, диагностике, нефропротекции. Вестн. соврем. клин. мед. 2014; 7 (1): 103-106.
  11. Brugts J.J., Uil C.A., Danser A.H.J., Boersma E. The renin-angiotensin-aldosterone system: approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease. J. Cardiol. 2009; 112: 303-312. http://dx.doi.org/10.1159/000159124
  12. Сoresh J., Selvin E., Stevens L.A. et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298 (17): 2038-2047. http://dx.doi.org/10.1001/jama.298.17.2038
  13. Ducharme A., Swedberg K., Pfeffer M.A. et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am. Heart J. 2006; 152 (1): 86-92. http://dx.doi.org/10.1016/j.ahj.2005.06.036
  14. Fliser D. Perspectives in renal disease progression: the endothelium as a treatment target in chronic kidney disease. J. Nephrol. 2010; 23 (4): 369-376.
  15. Haller H., Viberti G.C., Mimran A. et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J. Hypertens. 2006; 24 (2): 403-408. http://dx.doi.org/10.1097/01.hjh.0000202820.56201.e6
  16. Hoieggen A., Alderman M.H., Kjeldsen S.E. et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004; 66 (4): 1714-1715. http://dx.doi.org/10.1111/j.1523-1755.2004.938_8.x
  17. Iino Y., Hayashi M., Kawamura T. et al. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension-a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens. Res. 2004; 27 (1): 21-30. http://dx.doi.org/10.1291/hypres.27.21
  18. Konstam M.A., Neaton J.D., Dickstein K. et al. Eff ects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009; 374 (9704): 1840-1848. http://dx.doi.org/10.1016/S0140-6736(09)61913-9
  19. Maggioni A.P., Latini R., Carson P.E. et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am. Heart J. 2005; 149 (3): 548-557. http://dx.doi.org/10.1016/j.ahj.2004.09.033
  20. Matsushita K., Velde M., Astor В.С. et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375: 2073-2081. http://dx.doi.org/10.1016/S0140-6736(10)60674-5
  21. Mosterd A., Hoes A.W. Clinical epidemiology of heart failure. Heart. 2007; 93: 1137-1146. http://dx.doi.org/10.1136/hrt.2003.025270
  22. Page I.H. Hypertension mechanisms. New York: Grune and Stratton. Inc. 1987; 1102 p.
  23. Persson F., Rossing P., Hovind P. et al. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes. 2006; 55 (12): 3550-3555. http://dx.doi.org/10.2337/db06-0827
  24. Pfeffer M.A., McMurray J.J., Velazquez E.J. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 2003; 349 (20): 1893-1906. http://dx.doi.org/10.1056/NEJMoa032292
  25. Pitt B., Poole-Wilson P.A., Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000; 355 (9215): 1582-1587. http://dx.doi.org/10.1016/S0140-6736(00)02213-3
  26. Pohl M.A., Blumenthal S., Cordonnier D.J. et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J. Am. Nephrol. 2005; 16 (10): 3027-3037. http://dx.doi.org/10.1681/ASN.2004110919
  27. Remuzzi G., Ruggenenti P., Perna A. et al. RENAAL Study Group. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J. Am. Nephrol. 2004; 15 (12): 3117-3125. http://dx.doi.org/10.1097/01.ASN.0000146423.71226.0C
  28. Schmieder R.E., Delles C., Mimran A. et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007; 30 (6): 1351-1356. http://dx.doi.org/10.2337/dc06-1551
  29. The ONTARGEТ/TRANSCEND investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE-l-lntolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am. Heart J. 2004; 148: 52-61. http://dx.doi.org/10.1016/j.ahj.2004.03.020
  30. Viberti G., Wheeldon N.M. For the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure independent effect. Circulation. 2002; 106 (6): 672-678. http://dx.doi.org/10.1161/01.CIR.0000024416.33113.0A
  31. Zhu L., Carretero O.A., Xu J. et al. Angiotensin II type 2 receptor stimulated activation of plasma prekallikrein and bradykinin release: role of SHP-1. Am. J. Physiol. Heart Circ. Physiol. 2012; 302 (12): 2553-2559. http://dx.doi.org/10.1152/ajpheart.01157.2011

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

© 2015 Nasybullina A.A., Bulashova O.V., Khazova E.V., Gazizyanova V.M., Malkova M.I.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.




This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies